Stock Analysis

Myer Holdings (ASX:MYR) has become one of the more closely watched names in Australian retail, having reshaped itself into a substantially largerBusinesswhile grappling with a cautious consumer. The department-store operator has transformed its scale through the acquisition of the Apparel Brands portfolio from Premier …

archTIS (ASX:AR9) has quietly built one of the more compelling niche stories on the ASX small-cap technology board: data-centric security software sold into defence and government. The company's products, including NC Protect and the Kojensi secure collaboration platform, control access to sensitive information at …

Enero Group (ASX:EGG) used its FY26 results to make a case that discipline and margin can driveEarningseven when revenue is under pressure. TheMarketingand communications group, whose interests span digital advertising,Public Relationsand creative and technology services, delivered a result in August 2026 that showed the …

Temple & Webster (ASX:TPW) returned to the spotlight in August 2026 when the online furniture and homewares retailer delivered a record full-year result, while investors focused closely on a soft start to the new financial year. The combination of improving profitability and cautious near-term …

EBR Systems (ASX:EBR) is moving deeper into the commercialisation phase of its WiSE CRT System, with a fresh manufacturing milestone adding another component to its scale-up strategy. The US-based, ASX-listed medical technology company has developed a wireless endocardial pacing system designed for heart-failure patients …

Immutep (ASX:IMM) enters the second half of 2026 as a clinical-stage immuno-oncology company at a crossroads, after a major trial setback reshaped its pipeline narrative. The developer of eftilagimod alfa, an antigen-presenting-cell activator targeting the LAG-3 pathway, has spent the year absorbing a disappointment …

Botanix Pharmaceuticals (ASX:BOT) has moved from a development-stage biotech into an early commercial company, and its June-quarter results gave investors their clearest look yet at how the US launch of Sofdra is tracking after roughly its first full year on the market. Sofdra, a …